NCT04716426View on ClinicalTrials.gov

APT™ T3X on the COVID-19 Contamination Rate

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 28, 2021

Primary Completion Date

March 25, 2021

Study Completion Date

March 25, 2021

Conditions
COVID-19
Interventions
DRUG

Tetracycline hydrochloride 3%

Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.

DRUG

Placebo

Formulation composed of FDA approved inactive ingredients.

Trial Locations (1)

90035-074

Santa Casa de Misericórdia de Porto Alegre, Porto Alegre

All Listed Sponsors
collaborator

Santa Casa de Porto Alegre

OTHER

lead

University of Nove de Julho

OTHER

NCT04716426 - APT™ T3X on the COVID-19 Contamination Rate | Biotech Hunter | Biotech Hunter